Inflammasome Therapeutics Completes Enrollment in Study for First Oral Dual Inflammasome Inhibitor for Ophthalmic and Neuroinflammatory Diseases

NEWTON, Mass.--(BUSINESS WIRE)-- #ALS--Inflammasome Therapeutics, a private company, has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug K9, which has application in the treatment of multiple neuroinflammatory, degenerative diseases (such as Alzheimer’s, MS, ALS, Parkinson’s, geographic atrophy) and autoimmune diseases such as lupus and thyroid eye disease. “These diseases all involve a type of inflammation called inflammasome activation, and the activatio